CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Reid Waldman

Chief Executive Officer and Board Member, Veradermics, Incorporated

Search every verified Reid Waldman interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Reid Waldman, CEO and board member of Veradermics, appeared on a September 2026 podcast hosted by Dr. Ross Kopelman to discuss the company's development of a non-hormonal hair loss treatment. Waldman noted that current approved treatments, such as finasteride and topical minoxidil, have limitations, including high discontinuation rates for topicals and concerns about hormonal side effects. He cited recent regulatory actions, including an FDA label change in August 2021 acknowledging a risk of suicidality and suicidal behavior for finasteride, as well as reviews by UK and European regulators regarding mood-related risks. Waldman stated that Veradermics aims to address patient demand for alternatives to finasteride, though he did not disclose specific trial results or timelines. Waldman also discussed the commercial landscape for hair loss drugs, describing the market as traditionally cash-pay, similar to Botox, and said Veradermics is assessing payer strategies to ensure broad access upon approval. He reflected on his path from dermatology residency to founding a biotech company, saying he initially did not envision starting a company but pursued research with a tangible goal, hoping to help millions of patients rather than only individual ones. He emphasized that the company is rigorously evaluating the safety and efficacy of its candidate but made no promises about FDA approval.

Recent appearances

  • The First New Hair Loss Drug in 30 Years?

    September 15, 2026 · 📺 The Hair Doctors and Dr. Kopelman

    Sign up for our Digital Hair Loss Course: https://hairlosshandbook.com/ Dr. Ross Kopelman sits down with dermatologist and biotech founder Dr. Reid Waldman of Veradermics to explore what could come after finasteride. They discuss the limitations of current hair loss treatments, the growing demand for non-hormonal options and the future of treatment for both men and women. From finasteride safety concerns to the development of new therapies, this conversation offers an inside look at where medical hair loss treatment could be headed next. Interested in taking care of your hair loss? Kopelman…

    Watch on YouTube ↗

  • DPHL01 shows faster, stronger hair growth vs standard minoxidil in trial, CEO says | AAD 2026

    March 27, 2026 · 📺 Managed Healthcare Executive

    At the 2026 American Academy of Dermatology meeting, Reid Waldman, M.D., shared data showing that Veradermics’ investigational oral drug VDPHL01 produced faster, more consistent and greater hair growth than existing minoxidil treatments.

    Watch on YouTube ↗

  • Extended-Release Oral Minoxidil (VDPHL01) w/ Veradermics CEO Dr. Reid Waldman | HairStacks No.19

    March 04, 2026 · 📺 KwRx 🕊️

    Timestamps: 00:00:00 🧑‍⚕️ Importance of Specialized Care in Hair Loss 00:00:46 🧪 Overview of VDPHL01 and Its Mechanism 00:05:00 📊 Clinical Trial Results and Patient Response Preliminary phase two results indicate a high response rate, with 90.5% of patients showing noticeable improvement at month four. 00:11:58 📆 Inclusion Criteria for Clinical Trials Enrollment criteria allow participants aged 18 to 65, aiming to assess safety and efficacy across a broader age range. 00:13:30 🌟 Observations on Hair Recovery and Follicle Viability Patients with advanced hair loss (like Norwood types 3 to 5) sh…

    Watch on YouTube ↗

  • Veradermics CEO Dr Reid Waldman Reveals Why Now Was Perfect Time to List on NYSE

    February 12, 2026 · 📺 New York Stock Exchange

    Watch on YouTube ↗

  • Timely Topics S2 E15 | Ideas to Impact with Reid Waldman

    May 01, 2025 · 📺 UConn CCEI

    This week Jen is sitting down with Dr. Reid Waldman, founder and CEO of Veradermics. Reid is a board-certified dermatologist with more than 10 years of clinical experience. As a proud UConn alum, he has been committed to providing the state of Connecticut with paradigm-shifting solutions to common dermatological conditions. Learn more about The Collaboratory at CCEI: ccei.uconn.edu/collaboratory/ Follow UConn CCEI: LinkedIn: linkedin.com/company/connecticutcenterforentrepreneurshipandinnovation Instagram: instagram.com/uconnccei/ Twitter: x.com/UConnCCEI TikTok: tiktok.com/@…

    Watch on YouTube ↗

  • Journey from Dermatology Resident to Biotech CEO | Dr. Reid Waldman

    January 16, 2024 · 📺 Derm Club Podcast with Dr. Hannah Kopelman

    In this episode of the Derm Club Podcast, I had the pleasure of speaking with Dr. Reid Waldman, CEO of Veradermics and a Forbes 30 under 30 recognized board-certified dermatologist. We delved into his inspiring journey from dermatology residency to leading a cutting-edge biotech company. Dr. Waldman shared insights into Veradermics' innovative approaches to under-explored areas in dermatology, highlighting their phase two clinical trial for common warts using innovative dissolvable microarrays and the development of groundbreaking non-hormonal oral therapeutics for hair loss. He emphasized the…

    Watch on YouTube ↗

  • Reid Waldman | Exclusive Forbes Full Interview

    December 05, 2023 · 📺 Forbes

    0:00 Introduction 0:07 What Does Veradermics Do? 0:56 Fixing Hairless And Warts 3:08 Veradermics' Founding Story 4:56 Taking The Leap Into Entrepreneurship 5:39 Raising Almost $40 Million 8:22 Advantages Of Being Based In Connecticut 9:35 Would Reid Sell Veradermics? 10:50 "Not Everyone Gives Good Advice" 11:40 Finding The Right Mentors 12:03 Respecting What Others Know That You Don't 13:00 How Life Experience Helps Confidence 14:08 What's Next? 14:47 Thoughts On Legacy Read the full story on Forbes: https://www.forbes.com/30-under-30/2024/ Subscribe to FORBES: https://www.youtube.com/user/F…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →